YOLFTbeta
Nuvectis Pharma Inc

Nuvectis Pharma Inc

NVCT · NASDAQ · Healthcare / Biotechnology

20.24USD+0.01 (+0.05%)

Price History

Full chart

Market Stats

Previous Close20.23
Open20.17
Day Range19.60 – 20.38
52-Week Range5.55 – 29.28
Volume208.98K
Market Cap660.06M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.32
Dividend Yield0.00%
Beta-0.26
50-Day Avg21.53
200-Day Avg13.06

About

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ron Bentsur M.B.A.
  • Employees16
  • Headquarters1 Bridge Plaza, Fort Lee, NJ, United States, 07024, USA
  • Websitehttps://www.nuvectis.com

Leadership

  • Mr. Ron Bentsur M.B.A.Co-Founder, Chairman, CEO & President · b. 1966
  • Dr. Enrique Poradosu Ph.D.Co-Founder, Executive VP, Chief Scientific & Business Officer · b. 1967
  • Mr. Shay ShemeshCo-Founder, Executive VP, Chief Development & Operations Officer · b. 1984
  • Mr. Michael Carson CPAVice President of Finance · b. 1976

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0149.00K000
Growth (%)----100.00%--
Cost of Revenue-12.89M19.23M22.90M--
Gross Profit--12.89M-19.09M-22.90M--
Gross Margin---12808.72%---
Operating Expense-0149.00K0--
Operating Income-10.00K-12.89M-19.23M-22.90M-19.85M-27.57M
Operating Margin---12908.72%---
EBITDA-10.00K-12.89M-18.94M-22.26M-19.00M-26.44M
EBITDA Margin---12708.72%---
Net Income-10.00K-12.89M-18.79M-22.26M-19.00M-26.44M
Net Income Margin---12608.72%---
R&D-9.54M13.23M15.38M12.92M18.15M
R&D as % of Total Revenue--8877.18%---
Interest Expense04.00K149.00K---
Interest Expense % of Total Revenue--100.00%---

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.66M6.66M20.41M19.18M18.61M31.71M
Total Liabilities10.00K17.66M6.19M6.98M8.89M13.30M
Total Equity-10.00K-11.01M14.22M12.20M9.71M18.41M
Cash5.74M5.74M19.99M19.13M18.53M31.63M
Net Debt--5.74M-19.99M-19.13M-18.53M-31.63M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow24.00K-9.50M-13.56M-15.95M-12.25M-16.01M
Financing Cash Flow15.25M15.25M27.81M15.09M11.65M29.11M
Capital Expenditure000000
Free Cash Flow24.00K-9.50M-13.56M-15.95M-12.25M-16.01M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateOct 21, 2021Mar 22, 2022May 12, 2022Aug 10, 2022Nov 8, 2022Mar 7, 2023May 10, 2023Aug 9, 2023Nov 8, 2023Mar 5, 2024May 7, 2024Aug 6, 2024Nov 5, 2024Feb 25, 2025May 6, 2025Aug 5, 2025Nov 4, 2025Feb 11, 2026May 5, 2026Aug 4, 2026Nov 3, 2026
EPS Estimate0.00-0.85-0.22-0.24-0.27-0.38-0.45-0.21-0.34-0.36-0.39-0.31-0.25-0.26-0.25-0.25-0.25-0.31-0.31-0.25-0.22
EPS Actual-24.43-0.48-0.32-0.28-0.42-0.49-0.27-0.38-0.37-0.41-0.25-0.26-0.24-0.35-0.27-0.30-0.44-0.31-0.26-0.30-
Surprise-43.53%-45.45%-16.67%-55.56%-28.95%40.00%-80.95%-8.82%-13.89%35.90%16.13%4.00%-36.35%-8.00%-20.00%-76.00%0.00%16.13%-20.00%-
Timing-Pre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap660.06M
Enterprise Value664.02M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book75.55
EPS-1.32
Book Value0.34
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-214.58%
Return on Assets-73.07%
Shares Outstanding32.64M
Shares Float21.20M
Beta-0.26
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 6 analystsTarget 35.40
  • Strong Buy
    2
  • Buy
    4

Ownership Breakdown

Institutions
33.57%
Insiders
34.43%
Retail / Other
32.00%

Top Institutional Holders

  • Perceptive Advisors LLC
    1.00M3.10%
  • Soleus Capital Management, L.P.
    1.00M3.10%
  • Iridian Asset Management LLC
    777.08K2.41%
  • BlackRock Inc
    764.44K2.37%
  • Vanguard Capital Management, LLC
    659.88K2.04%
  • Occam Crest Management L.P.
    407.15K1.26%
  • Geode Capital Management, LLC
    384.11K1.19%
  • Baldwin Brothers Inc
    382.01K1.18%
  • Avidity Partners Management LP
    200.00K0.62%
  • State Street Corp
    166.52K0.52%
  • Northern Trust Corp
    124.21K0.38%
  • Citadel Advisors Llc
    115.53K0.36%
  • Vanguard Fiduciary Trust Co
    114.84K0.36%
  • Susquehanna International Group, LLP
    105.29K0.33%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    650.49K2.02%
  • iShares Russell 2000 ETF
    430.82K1.33%
  • Fidelity Small Cap Index
    185.54K0.57%
  • iShares Russell 2000 Growth ETF
    161.77K0.50%
  • Vanguard Russell 2000 ETF
    98.23K0.30%
  • Fidelity Enhanced Small Cap Core ETF
    97.12K0.30%